Chrysalis is a specialist strategy and commercialisation partner for high-growth health, medtech and life sciences ventures across Australia and Asia.
Discover our approachChrysalis has evolved from a strategy consultancy into a boutique venture partner dedicated to health, medtech and life sciences. We partner deeply with a select portfolio of 4–6 ventures at any given time — co-founding companies from concept through to commercialisation, or acquiring and transforming established businesses through a disciplined buy-and-build strategy.
We bring strategic management, clinical validation, and access to capital under one roof. Our team has deep domain expertise across health, finance, and operations — and we deploy it with a founder's conviction, not a consultant's detachment.
End-to-end strategic leadership across innovation, product development, growth strategy, organisation and operating model design, IP and risk management, and operational systems. We don't advise from the sidelines — we operate.
Specialist clinical advisory to de-risk health and medtech assets. Research governance, clinical trial protocols, KOL engagement, and scientific advisory to build the evidence base that underpins value.
Proprietary deal flow and impact-driven investment from seed through to growth stages. We invest our own capital alongside co-investors with a buy-and-build thesis.
We partner across the full lifecycle — from co-founding through to acquisition — bringing deep capability to de-risk assets and drive them to strategic value inflection points.
Co-founded, led and de-risked a Gates Foundation funded opportunity. Raised $17m in capital to de-risk product, IP and manufacturing development and deliver successful pilot clinical trials. Now targeting significant clinical and commercial milestones for long-term value creation.
Originated and managed acquisition of a 30+ year profitable business. Executing a buy-and-build strategy to transform the business into a scaled platform with multiples of its original revenue.
Conceptualised, originated, and transacted a $10m deal to establish a fast-growing ophthalmology clinical trials business. A wholly owned subsidiary of the Centre for Eye Research Australia (CERA).
A biopsy-free skin cancer diagnostic platform. The DermR® Patch painlessly extracts live skin cells via microneedle, paired with a proprietary genetic test delivering ~99% sensitivity and ~96% specificity — on a mission to replace 1 billion avoidable biopsies.
Pioneering next-generation polymeric heart valves designed to outlast current options and eliminate lifelong anticoagulant therapy. Backed by NSW Government funding with deep academic ties to the University of Sydney.
Molecular diagnostics, genetic testing, AI-enabled clinical decision support and software as a medical device.
Novel implants, point-of-care diagnostics, smart surgical instruments and connected wearable technologies.
Polymeric biomaterials, tissue engineering, advanced wound care and regenerative therapies.
Clinical trials, contract research, laboratory services, and medtech services spanning equipment manufacture, calibration, testing and regulatory compliance.
If you're a founder, researcher, or operator with a transformational health asset — we'd like to hear from you.